Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 29.07 Million SEK | -37.74% |
| 2022 | 46.69 Million SEK | -12.91% |
| 2021 | 53.61 Million SEK | 72.98% |
| 2020 | 30.99 Million SEK | 197.23% |
| 2019 | 10.42 Million SEK | 47.11% |
| 2018 | 7.08 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 6.02 Million SEK | -8.71% |
| 2023 Q4 | 7.04 Million SEK | 16.86% |
| 2023 Q1 | 10.81 Million SEK | 16.33% |
| 2023 Q2 | 6.6 Million SEK | -38.98% |
| 2023 FY | 32.08 Million SEK | -31.29% |
| 2022 Q3 | 15.77 Million SEK | 48.78% |
| 2022 Q4 | 9.29 Million SEK | -41.07% |
| 2022 Q2 | 10.6 Million SEK | -3.69% |
| 2022 Q1 | 11.01 Million SEK | -16.83% |
| 2022 FY | 46.69 Million SEK | -12.91% |
| 2021 Q1 | 12.5 Million SEK | -9.76% |
| 2021 Q4 | 13.23 Million SEK | 29.65% |
| 2021 Q3 | 10.21 Million SEK | -42.2% |
| 2021 Q2 | 17.66 Million SEK | 41.33% |
| 2021 FY | 53.61 Million SEK | 72.98% |
| 2020 FY | 30.99 Million SEK | 197.23% |
| 2020 Q4 | 13.85 Million SEK | 130.98% |
| 2020 Q3 | 5.99 Million SEK | 14.03% |
| 2020 Q2 | 5.25 Million SEK | -10.68% |
| 2020 Q1 | 5.88 Million SEK | 0.0% |
| 2019 FY | 10.42 Million SEK | 47.11% |
| 2018 FY | 7.08 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alzinova AB (publ) | 36.39 Million SEK | 20.123% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -98.403% |
| BioArctic AB (publ) | 89.62 Million SEK | 67.563% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.08% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.256% |
| Cantargia AB (publ) | 290.01 Million SEK | 89.976% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -32.779% |
| Genovis AB (publ.) | 88.19 Million SEK | 67.037% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 74.736% |
| Mendus AB (publ) | 129.13 Million SEK | 77.487% |
| Kancera AB (publ) | 63.07 Million SEK | 53.91% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -426.762% |
| LIDDS AB (publ) | 27.75 Million SEK | -4.756% |
| Lipum AB (publ) | 37.3 Million SEK | 22.074% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -300.772% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 78.61% |
| NextCell Pharma AB | -576.01 Thousand SEK | 5147.056% |
| OncoZenge AB (publ) | 15.9 Million SEK | -82.785% |
| Saniona AB (publ) | 1.07 Million SEK | -2599.35% |
| Simris Alg AB (publ) | 38.64 Million SEK | 24.766% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 90.958% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 91.871% |
| Xintela AB (publ) | 57.31 Million SEK | 49.278% |
| Ziccum AB (publ) | 27.87 Million SEK | -4.283% |
| AcouSort AB (publ) | 25.87 Million SEK | -12.351% |
| Active Biotech AB (publ) | 44.8 Million SEK | 35.12% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -2.632% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -77.257% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -300.0% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.003% |
| CombiGene AB (publ) | 44.14 Million SEK | 34.143% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 79.668% |
| Intervacc AB (publ) | 79.78 Million SEK | 63.562% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.533% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 31.807% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -64.406% |
| Corline Biomedical AB | 30.16 Million SEK | 3.633% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 49.903% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 65.045% |
| Aptahem AB (publ) | 10.01 Million SEK | -190.344% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 78.416% |
| Fluicell AB (publ) | 28.61 Million SEK | -1.59% |
| Biovica International AB (publ) | 133.72 Million SEK | 78.259% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -46.902% |
| Abliva AB (publ) | 27.86 Million SEK | -4.328% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 84.976% |
| 2cureX AB (publ) | 36.51 Million SEK | 20.39% |
| I-Tech AB | 40.14 Million SEK | 27.588% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.617% |
| Cyxone AB (publ) | 28.21 Million SEK | -3.041% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 73.418% |
| Biosergen AB | 26.8 Million SEK | -8.441% |
| Nanologica AB (publ) | 69.88 Million SEK | 58.401% |
| SynAct Pharma AB | 224.49 Million SEK | 87.05% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 34.191% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.414% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -21.365% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 89.966% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -270.048% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 73.789% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -97.769% |